IPHARMA obtained an approval to conduct the clinical trial on COVID-19
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II/III clinical trial of the drug opaganib, a sphingosine kinase-2 (SK2), to treat patients with COVID-19 pneumonia.
The investigational drug developer is RedHill Biopharma Ltd. (Israel).
Protocol № ABC-201 "Opaganib, a sphingosine kinase-2 (SK2) inhibitor in COVID-19 pneumonia: a randomized double-blind placebo-controlled Phase II/III study in adult subjects hospitalized with severe SARS-CoV-2 positive pneumonia".
The purpose is to assess safety and tolerability of opaganib in adult subjects hospitalized with severe SARS-CoV-2 positive pneumonia.
The study will be conducted in 19 clinical sites.
Исследование будет проводиться в 19 клинических центрах.